{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:14:54Z","timestamp":1781190894992,"version":"3.54.1"},"reference-count":198,"publisher":"The Pediatric Pharmacy Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Respiratory syncytial virus (RSV) is a major contributor to global morbidity and mortality, disproportionately affecting young children and infants. Annual worldwide estimates suggest more than 30 million cases of lower respiratory infection and 100,000 deaths are attributed to RSV in children younger than 5 years of age, making RSV prevention and treatment a global priority. Recently approved monoclonal antibodies and vaccines for the prevention of RSV in infants and children have the potential to significantly alter disease burden. Disease prevention is paramount as treatments with rigorously proven clinical efficacy are limited, and supportive care remains the primary management strategy for the majority of patients who contract RSV. However, new entities continue to be evaluated for the treatment of RSV in the pediatric population. This review aimed to synthesize and evaluate existing data on the approved RSV preventative therapies nirsevimab, RSVpreF, clesrovimab, and palivizumab. RSV disease, including its spread, virology, diagnosis, clinical presentation, and treatment, is also discussed.<\/jats:p>","DOI":"10.5863\/jppt-25-00075","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:35:13Z","timestamp":1776472513000},"page":"322-338","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics"],"prefix":"10.5863","volume":"31","author":[{"given":"J. Hunter","family":"Fly","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science (JHF), The University of Tennessee Health Science Center College of Pharmacy, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Stultz","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Translational Science (JSS), The University of Tennessee Health Science Center College of Pharmacy, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea S.","family":"Eiland","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (LSE), Auburn University Harrison College of Pharmacy, Auburn, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"JPPT-25-00075-b01","series-title":"Int J Infect Dis","first-page":"70","article-title":"Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study","volume":"135","author":"Du","year":"2023","unstructured":"Du Y, Yan R, Wu X, et al. Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study. Int J Infect Dis. 2023;135:70\u201376."},{"issue":"10340","key":"JPPT-25-00075-b02","series-title":"Lancet","first-page":"2047","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u20132064."},{"issue":"Suppl 2","key":"JPPT-25-00075-b03","series-title":"J Infect Dis","first-page":"S154","article-title":"Respiratory syncytial virus is the leading cause of united states infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample","volume":"226","author":"Suh","year":"2022","unstructured":"Suh M, Movva N, Jiang X, et al. Respiratory syncytial virus is the leading cause of united states infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample. J Infect Dis. 2022;226(Suppl 2):S154\u2013S163."},{"key":"JPPT-25-00075-b04","series-title":"RSV surveillance & research","unstructured":"Centers for Disease Control Prevention. RSV surveillance & research. Updated August 30, 2024. Accessed November 22, 2024. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/index.html"},{"issue":"5","key":"JPPT-25-00075-b05","series-title":"J Infect Dis","first-page":"1318","article-title":"Annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus among US infants aged <12 months","volume":"231","author":"Houde","year":"2025","unstructured":"Houde L, Law AW, Averin A, et al. Annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus among US infants aged <12 months. J Infect Dis. 2025;231(5):1318\u20131326."},{"issue":"2","key":"JPPT-25-00075-b06","series-title":"J Pediatr Pharmacol Ther","first-page":"75","article-title":"Respiratory syncytial virus: diagnosis, treatment and prevention","volume":"14","author":"Eiland","year":"2009","unstructured":"Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75\u201385."},{"key":"JPPT-25-00075-b07","series-title":"Principles and Practice of Pediatric Infectious Diseases","first-page":"213","article-title":"Respiratory syncytial virus","author":"Tristram","year":"2003","unstructured":"Tristram DA, Welliver RC. Respiratory syncytial virus. In: Long SS, Pickering LK, Prober CG, editors. Principles and Practice of Pediatric Infectious Diseases. 2nd ed. New York, NY: Churchill Livingstone; 2003:213\u2013218."},{"issue":"3","key":"JPPT-25-00075-b08","series-title":"Proc Soc Exp Biol Med","first-page":"544","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Blount","year":"1956","unstructured":"Blount Re Jr, Morris Ja, Savage Re. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956;92(3):544\u2013549."},{"issue":"Supplement_2","key":"JPPT-25-00075-b09","series-title":"J Pediatric Infect Dis Soc","first-page":"S103","article-title":"A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy","volume":"13","author":"Noor","year":"2024","unstructured":"Noor A, Krilov LR. A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy. J Pediatric Infect Dis Soc. 2024;13(Supplement_2):S103\u2013S109."},{"issue":"1","key":"JPPT-25-00075-b10","series-title":"Infect Dis Ther","first-page":"87","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87\u2013120."},{"issue":"6136","key":"JPPT-25-00075-b11","series-title":"Science","first-page":"1113","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","unstructured":"McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113\u20131117."},{"issue":"1","key":"JPPT-25-00075-b12","series-title":"Ann Pharmacother","first-page":"81","article-title":"Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children","volume":"59","author":"Fly","year":"2025","unstructured":"Fly JH, Eiland LS, Stultz JS. Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children. Ann Pharmacother. 2025;59(1):81\u201391."},{"issue":"8","key":"JPPT-25-00075-b13","series-title":"Ann Pharmacother","first-page":"758","article-title":"Maternal RSVpreF vaccine: a novel agent for respiratory syncytial virus prevention in infants","volume":"59","author":"Fly","year":"2025","unstructured":"Fly JH, Stultz JS, Eiland LS. Maternal RSVpreF vaccine: a novel agent for respiratory syncytial virus prevention in infants. Ann Pharmacother. 2025;59(8):758\u2013766."},{"issue":"3","key":"JPPT-25-00075-b14","series-title":"Cureus","first-page":"e36342","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","year":"2023","unstructured":"Kaler J, Hussain A, Patel K, et al. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3):e36342."},{"issue":"4","key":"JPPT-25-00075-b15","series-title":"Nat Rev Microbiol","first-page":"233","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","unstructured":"Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233\u2013245."},{"issue":"14","key":"JPPT-25-00075-b16","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"355","article-title":"Seasonality of respiratory syncytial virus - United States, 2017-2023","volume":"72","author":"Hamid","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355\u2013361."},{"issue":"6","key":"JPPT-25-00075-b17","series-title":"Med Mal Infect","first-page":"377","article-title":"Respiratory syncytial virus infection in elderly adults","volume":"48","author":"Haber","year":"2018","unstructured":"Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377\u2013382."},{"issue":"3","key":"JPPT-25-00075-b18","series-title":"Am J Respir Crit Care Med","first-page":"308","article-title":"Evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies?","volume":"194","author":"Kulkarni","year":"2016","unstructured":"Kulkarni H, Smith CM, Lee Ddo H, et al. Evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies? Am J Respir Crit Care Med. 2016;194(3):308\u2013316."},{"key":"JPPT-25-00075-b19","series-title":"Douglas and Bennett\u2019s Principles and Practice of Infectious Diseases","first-page":"1782","article-title":"Respiratory syncytial virus","author":"Hall","year":"2000","unstructured":"Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett\u2019s Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingston; 2000:1782\u20131801"},{"issue":"3","key":"JPPT-25-00075-b20","series-title":"Respir Care","first-page":"209","article-title":"Systematic review of the biology and medical management of respiratory syncytial virus infection","volume":"48","author":"Black","year":"2003","unstructured":"Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care. 2003;48(3):209\u2013233."},{"issue":"10","key":"JPPT-25-00075-b21","series-title":"Thorax","first-page":"986","article-title":"Respiratory syncytial virus (RSV): a scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","unstructured":"Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019;74(10):986\u2013993."},{"issue":"Suppl B","key":"JPPT-25-00075-b22","series-title":"Respir Med","first-page":"S1","article-title":"An update on respiratory syncytial virus epidemiology: a developed country perspective","volume":"96","author":"Law","year":"2002","unstructured":"Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med. 2002;96 Suppl B:S1\u2013S7."},{"issue":"29","key":"JPPT-25-00075-b23","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1013","article-title":"Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021","volume":"70","author":"Olsen","year":"2021","unstructured":"Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013\u20131019."},{"issue":"1","key":"JPPT-25-00075-b24","series-title":"Mod Pathol","first-page":"108","article-title":"The histopathology of fatal untreated human respiratory syncytial virus infection","volume":"20","author":"Johnson","year":"2007","unstructured":"Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108\u2013119."},{"issue":"5","key":"JPPT-25-00075-b25","series-title":"Arch Dis Child","first-page":"428","article-title":"Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection","volume":"71","author":"Everard","year":"1994","unstructured":"Everard ML, Swarbrick A, Wrightham M, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child. 1994;71(5):428\u2013432."},{"issue":"14","key":"JPPT-25-00075-b26","series-title":"Int J Biol Sci","first-page":"4073","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","unstructured":"Shang Z, Tan S, Ma D. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. Int J Biol Sci. 2021;17(14):4073\u20134091."},{"key":"JPPT-25-00075-b27","series-title":"BMJ","first-page":"f7027","article-title":"Duration of symptoms of respiratory tract infections in children: systematic review [published correction appears in BMJ. 2014;347:f7575]","volume":"347","author":"Thompson","year":"2013","unstructured":"Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review [published correction appears in BMJ. 2014;347:f7575]. BMJ. 2013;347:f7027."},{"issue":"11","key":"JPPT-25-00075-b28","series-title":"Pediatr Rev","first-page":"568","article-title":"Bronchiolitis","volume":"40","author":"Silver","year":"2019","unstructured":"Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev. 2019;40(11):568\u2013576."},{"issue":"3","key":"JPPT-25-00075-b29","series-title":"Demographics and outcome. Am J Dis Child","first-page":"247","article-title":"Respiratory syncytial virus-related apnea in infants","volume":"138","author":"Church","year":"1984","unstructured":"Church NR, Anas NG, Hall CB, et al Respiratory syncytial virus-related apnea in infants. Demographics and outcome. Am J Dis Child. 1984;138(3):247\u2013250."},{"issue":"3","key":"JPPT-25-00075-b30","series-title":"J Pediatr","first-page":"382","article-title":"Apnea associated with respiratory syncytial virus infection in young infants","volume":"90","author":"Bruhn","year":"1977","unstructured":"Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J Pediatr. 1977;90(3):382\u2013386."},{"issue":"16","key":"JPPT-25-00075-b31","series-title":"N Engl J Med","first-page":"1451","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u20131464."},{"issue":"5","key":"JPPT-25-00075-b32","series-title":"N Engl J Med","first-page":"415","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415\u2013425."},{"issue":"9","key":"JPPT-25-00075-b33","series-title":"N Engl J Med","first-page":"837","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u2013846."},{"issue":"16","key":"JPPT-25-00075-b34","series-title":"N Engl J Med","first-page":"1533","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","unstructured":"Muller WJ, Madhi SA, Seoane Nu\u00f1ez B, et al; MELODY Study Group. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533\u20131534."},{"issue":"9","key":"JPPT-25-00075-b35","series-title":"N Engl J Med","first-page":"892","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"Domachowske","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EAF, et al; MEDLEY Study Group. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892\u2013894."},{"issue":"1","key":"JPPT-25-00075-b36","series-title":"Pediatrics","first-page":"e2023061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"152","author":"Caserta","year":"2023","unstructured":"Caserta MT, O\u2019Leary ST, Munoz FM, et al. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2023;152(1):e2023061803."},{"issue":"6","key":"JPPT-25-00075-b37","series-title":"Am J Dis Child","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","unstructured":"Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543\u2013546."},{"issue":"10","key":"JPPT-25-00075-b38","series-title":"N Engl J Med","first-page":"530","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children","volume":"300","author":"Henderson","year":"1979","unstructured":"Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300(10):530\u2013534."},{"issue":"4","key":"JPPT-25-00075-b39","series-title":"J Infect Dis","first-page":"814","article-title":"Severity of respiratory syncytial virus infection is related to virus strain","volume":"175","author":"Walsh","year":"1997","unstructured":"Walsh EE, McConnochie KM, Long CE, et al. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis. 1997;175(4):814\u2013820."},{"issue":"1","key":"JPPT-25-00075-b40","series-title":"J Infect Dis","first-page":"54","article-title":"Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons","volume":"193","author":"Gilca","year":"2006","unstructured":"Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193(1):54\u201358."},{"issue":"5","key":"JPPT-25-00075-b41","series-title":"Pediatrics","first-page":"e1474","article-title":"Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015;136(4):782. doi: 10.1542\/peds.2015-2862.]","volume":"134","author":"Ralston","year":"2014","unstructured":"Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015;136(4):782. doi: 10.1542\/peds.2015-2862.]. Pediatrics. 2014;134(5):e1474\u2013e1502."},{"issue":"11 Suppl","key":"JPPT-25-00075-b42","series-title":"Pediatr Infect Dis J","first-page":"S36","article-title":"Diagnostic assays for respiratory syncytial virus disease","volume":"26","author":"Henrickson","year":"2007","unstructured":"Henrickson KJ, Hall CB. Diagnostic assays for respiratory syncytial virus disease. Pediatr Infect Dis J. 2007;26(11 Suppl):S36\u2013S40."},{"issue":"11","key":"JPPT-25-00075-b43","series-title":"J Infect Dis","first-page":"1516","article-title":"Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis","volume":"228","author":"Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C, Atwell J, Moreo LM, et al. Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis. J Infect Dis. 2023;228(11):1516\u20131527."},{"key":"JPPT-25-00075-b44","series-title":"Red Book: 2024-2027 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2024","unstructured":"Kimberlin DW, Banerjee R, Barnett ED, et al. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. 33rd ed. Washington, DC: American Academy of Pediatrics; 2024."},{"key":"JPPT-25-00075-b45","year":"2021","unstructured":"Palivizumab [package insert]. Gaithersburg, MD: MedImmune, LLC; 2021."},{"issue":"2","key":"JPPT-25-00075-b46","series-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics","first-page":"e620","article-title":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee","volume":"134","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620\u2013e638."},{"key":"JPPT-25-00075-b47","article-title":"AAP recommendations for the prevention of RSV disease in infants and children","unstructured":"American Academy of Pediatrics. AAP recommendations for the prevention of RSV disease in infants and children. Updated July 8, 2025. Accessed July 9, 2025. https:\/\/publications.aap.org\/redbook\/resources\/25379\/AAP-Recommendations-for-the-Prevention-of-RSV"},{"key":"JPPT-25-00075-b48","article-title":"SYNAGIS to be discontinued","unstructured":"Swedish Orphan Biovitrum. SYNAGIS to be discontinued. Accessed August 13, 2025. https:\/\/www.synagis.com\/index.html"},{"issue":"3 Pt 1","key":"JPPT-25-00075-b49","series-title":"Pediatrics","first-page":"):531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1 ):531\u2013537."},{"issue":"4","key":"JPPT-25-00075-b50","series-title":"J Pediatr","first-page":"532","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532\u2013540."},{"key":"JPPT-25-00075-b51","article-title":".","year":"2023","unstructured":"Beyfortus (nirsevimab-alip) [package insert] . S\u00f6dert\u00e4lje, Sweden: Astrazenca AB; 2023."},{"issue":"388","key":"JPPT-25-00075-b52","series-title":"Sci Transl Med","first-page":"eaaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","unstructured":"Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928."},{"issue":"9","key":"JPPT-25-00075-b53","series-title":"Vaccines (Basel)","first-page":"961","article-title":"Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities","volume":"9","author":"Ananworanich","year":"2021","unstructured":"Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines (Basel). 2021;9(9):961."},{"key":"JPPT-25-00075-b54","series-title":"Biomed Pharmacother","first-page":"115851","article-title":"Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults","volume":"169","author":"Phuah","year":"2023","unstructured":"Phuah JY, Maas BM, Tang A, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother. 2023;169:115851."},{"issue":"34","key":"JPPT-25-00075-b55","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"920","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Jones","year":"2023","unstructured":"Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920\u2013925."},{"issue":"41","key":"JPPT-25-00075-b56","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1115","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Fleming-Dutra","year":"2023","unstructured":"Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115\u20131122."},{"issue":"3","key":"JPPT-25-00075-b57","series-title":"Lancet Child Adolesc Health","first-page":"180","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180\u2013189."},{"issue":"26","key":"JPPT-25-00075-b58","series-title":"N Engl J Med","first-page":"2425","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425\u20132435."},{"issue":"4","key":"JPPT-25-00075-b59","series-title":"Pediatrics","first-page":"e2024066508","article-title":"Safety and pharmacokinetics of nirsevimab in immunocompromised children","volume":"154","author":"Domachowske","year":"2024","unstructured":"Domachowske J, Hamr\u00e9n UW, Banu I, et al. Safety and pharmacokinetics of nirsevimab in immunocompromised children. Pediatrics. 2024;154(4):e2024066508."},{"key":"JPPT-25-00075-b60","series-title":"package insert","year":"2025","unstructured":"Enflonsia (clesrovimab-cfor) [package insert]. Rahway, New Jersey: Merck Sharp & Dohme LLC; 2025."},{"key":"JPPT-25-00075-b61","article-title":"Child immunization schedule addendum","unstructured":"Centers for Disease Control and Prevention. Child immunization schedule addendum. Updated August 7, 2025. Accessed August 13, 2025. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-addendum.html"},{"key":"JPPT-25-00075-b62","article-title":"Centers for Disease Control and Prevention, Sinha A. Clesrovimab (MK-1654): pediatric clinical program presentation to the Advisory Committee on Immunization Practices","unstructured":"Centers for Disease Control and Prevention, Sinha A. Clesrovimab (MK-1654): pediatric clinical program presentation to the Advisory Committee on Immunization Practices. Updated October 2024. Accessed February 27, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/02-rsv-mat-peds-sinha-508.pdf"},{"key":"JPPT-25-00075-b63","article-title":"Efficacy and safety of clesrovimab (MK-1654) in infants (MK-1654-004) (CLEVER)","unstructured":"National Library of Medicine. Merck Sharp & Dohme LLC. Efficacy and safety of clesrovimab (MK-1654) in infants (MK-1654-004) (CLEVER). Accessed February 27, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04767373"},{"key":"JPPT-25-00075-b64","article-title":"Clesrovimab (MK- 1654) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease (MK-1654-007) (SMART)","unstructured":"National Library of Medicine. Merck Sharp & Dohme LLC. Clesrovimab (MK- 1654) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease (MK-1654-007) (SMART). Accessed February 27, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04938830"},{"issue":"Suppl 1","key":"JPPT-25-00075-b65","series-title":"Open Forum Infect Dis","first-page":"ofae631.003","article-title":"Abstract 166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants","volume":"12","author":"Zar","year":"2025","unstructured":"Zar HJ, Simoes E, Madhi S, et al. Abstract 166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.003."},{"key":"JPPT-25-00075-b66","article-title":"Abryvso (Respiratory Syncytial Virus Vaccine) [package insert]","year":"2023","unstructured":"Abryvso (Respiratory Syncytial Virus Vaccine) [package insert]. New York, NY: Pfizer, Inc; 2023."},{"issue":"17","key":"JPPT-25-00075-b67","series-title":"N Engl J Med","first-page":"1615","article-title":"Prefusion F protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","unstructured":"Sim\u00f5es EAF, Center KJ, Tita ATN, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615\u20131626."},{"key":"JPPT-25-00075-b68","article-title":"Evidence to recommendations framework updates Pfizer maternal RSVpreF vaccine","author":"Fleming-Dutra","unstructured":"Centers for Disease Control and Prevention, Fleming-Dutra K. Evidence to recommendations framework updates Pfizer maternal RSVpreF vaccine. Updated September 2023. Accessed February 17, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-09-22\/06-Mat-Peds-Fleming-Dutra-508.pdf"},{"key":"JPPT-25-00075-b69","article-title":"Evidence to recommendations framework: Pfizer maternal RSVpreF vaccine. Updated","author":"Fleming-Dutra K","year":"2023","unstructured":"Centers for Disease Control and Prevention, Fleming-Dutra K. Evidence to recommendations framework: Pfizer maternal RSVpreF vaccine. Updated June 2023. Accessed February,26 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-06-21-23\/03-RSV-Mat-Ped-Fleming-Dutra-508.pdf"},{"issue":"21","key":"JPPT-25-00075-b70","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"489","article-title":"Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024 [published correction appears in MMWR Morb Mortal Wkly Rep. 2024;73(27):612. doi: 10.15585\/mmwr.mm7327a4.]","volume":"73","author":"Hause","year":"2024","unstructured":"Hause AM, Moro PL, Baggs J, et al. Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024 [published correction appears in MMWR Morb Mortal Wkly Rep. 2024;73(27):612. doi: 10.15585\/mmwr.mm7327a4.]. MMWR Morb Mortal Wkly Rep. 2024;73(21):489\u2013494."},{"key":"JPPT-25-00075-b71","series-title":"Updated October","first-page":"2024","article-title":"and","volume":"23","author":"Prevention","unstructured":"Centers for Disease Control and Prevention, DeSilva M. RSVpreF vaccine, preterm birth, and small for gestational age at birth preliminary results from the vaccine safety datalink. Updated October 23, 2024. Assessed February 26, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/03-RSV-Mat-Peds-DeSilva-508.pdf"},{"key":"JPPT-25-00075-b72","article-title":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV6120\/\u0394NS1 and RSV 6120\/F1\/G2\/\u0394NS1, in RSV-seropositive children and RSV-seronegative infants and children","unstructured":"National Library of Medicine. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV6120\/\u0394NS1 and RSV 6120\/F1\/G2\/\u0394NS1, in RSV-seropositive children and RSV-seronegative infants and children. Accessed May 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03596801"},{"key":"JPPT-25-00075-b73","article-title":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine, LID\/\u0394M2-2\/1030s, in RSV-seronegative infants and children 6 to 24 months of age","unstructured":"National Library of Medicine. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine, LID\/\u0394M2-2\/1030s, in RSV-seronegative infants and children 6 to 24 months of age. Accessed May 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04520659"},{"key":"JPPT-25-00075-b74","article-title":"Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting December 12, 2024. FDA briefing document. Considerations for respiratory syncytial virus (RSV) vaccine safety in pediatric populations","unstructured":"Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting December 12, 2024. FDA briefing document. Considerations for respiratory syncytial virus (RSV) vaccine safety in pediatric populations. Accessed May 1, 2025. https:\/\/www.fda.gov\/media\/184301\/download"},{"key":"JPPT-25-00075-b75","series-title":"Cochrane Database Syst Rev","first-page":"CD004873","article-title":"Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old","volume":"4","author":"Roqu\u00e9-Figuls","year":"2023","unstructured":"Roqu\u00e9-Figuls M, Gin\u00e9-Garriga M, Granados Rugeles C, et al. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2023;4:CD004873."},{"key":"JPPT-25-00075-b76","series-title":"Cochrane Database Syst Rev","first-page":"CD010473","article-title":"Continuous positive airway pressure (CPAP) for acute bronchiolitis in children","volume":"4","author":"Jat","year":"2022","unstructured":"Jat KR, Dsouza JM, Mathew JL. Continuous positive airway pressure (CPAP) for acute bronchiolitis in children. Cochrane Database Syst Rev. 2022;4:CD010473."},{"key":"JPPT-25-00075-b77","series-title":"Cochrane Database Syst Rev","first-page":"CD009609","article-title":"High-flow nasal cannula therapy for infants with bronchiolitis","volume":"3","author":"Armarego","year":"2024","unstructured":"Armarego M, Forde H, Wills K, Beggs SA. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2024;3:CD009609."},{"key":"JPPT-25-00075-b78","series-title":"Cochrane Database Syst Rev","first-page":"CD006458","article-title":"Nebulised hypertonic saline solution for acute bronchiolitis in infants","volume":"4","author":"Zhang","year":"2023","unstructured":"Zhang L, Mendoza-Sassi RA, Wainwright CE, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2023;4:CD006458."},{"issue":"9","key":"JPPT-25-00075-b79","series-title":"J Paediatr Child Health","first-page":"1125","article-title":"Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: a retrospective study","volume":"55","author":"Stobbelaar","year":"2019","unstructured":"Stobbelaar K, Kool M, de Kruijf D, et al. Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: a retrospective study. J Paediatr Child Health. 2019;55(9):1125\u20131132."},{"key":"JPPT-25-00075-b80","series-title":"Cochrane Database Syst Rev","first-page":"CD006915","article-title":"Heliox inhalation therapy for bronchiolitis in infants","volume":"9","author":"Liet","year":"2015","unstructured":"Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2015;9:CD006915."},{"key":"JPPT-25-00075-b81","series-title":"Cochrane Database Syst Rev","first-page":"CD001266","article-title":"Bronchodilators for bronchiolitis","volume":"6","author":"Gadomski","year":"2014","unstructured":"Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;6:CD001266."},{"key":"JPPT-25-00075-b82","series-title":"Cochrane Database Syst Rev","first-page":"CD004878","article-title":"Glucocorticoids for acute viral bronchiolitis in infants and young children","volume":"6","author":"Fernandes","year":"2013","unstructured":"Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013;6:CD004878."},{"key":"JPPT-25-00075-b83","series-title":"Cochrane Database Syst Rev","first-page":"CD005189","article-title":"Antibiotics for bronchiolitis in children under two years of age","volume":"10","author":"Farley","year":"2014","unstructured":"Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 2014;10:CD005189."},{"issue":"10","key":"JPPT-25-00075-b84","series-title":"Cochrane Database Syst Rev","first-page":"CD009417","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","volume":"10","author":"Sanders","year":"2023","unstructured":"Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev. 2023;10(10):CD009417."},{"issue":"3","key":"JPPT-25-00075-b85","series-title":"Pediatrics","first-page":"e20182308","article-title":"Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial","volume":"143","author":"Alansari","year":"2019","unstructured":"Alansari K, Toaimah FH, Almatar DH, et al. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics. 2019;143(3):e20182308."},{"key":"JPPT-25-00075-b86","series-title":"Cochrane Database Syst Rev","first-page":"CD009194","article-title":"Surfactant therapy for bronchiolitis in critically ill infants","volume":"8","author":"Jat","year":"2015","unstructured":"Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev. 2015;8:CD009194."},{"issue":"2","key":"JPPT-25-00075-b87","series-title":"Allergy Asthma Proc","first-page":"147","article-title":"Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial","volume":"31","author":"Zedan","year":"2010","unstructured":"Zedan M, Gamil N, El-Assmy M, et al. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. Allergy Asthma Proc. 2010;31(2):147\u2013153."},{"issue":"6","key":"JPPT-25-00075-b88","series-title":"Pediatrics","first-page":"e1249","article-title":"A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis","volume":"122","author":"Amirav","year":"2008","unstructured":"Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics. 2008;122(6):e1249\u2013e1255."},{"key":"JPPT-25-00075-b89","series-title":"Cochrane Database Syst Rev","first-page":"CD010636","article-title":"Leukotriene inhibitors for bronchiolitis in infants and young children","volume":"3","author":"Liu","year":"2015","unstructured":"Liu F, Ouyang J, Sharma AN, et al. Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2015;3:CD010636."},{"key":"JPPT-25-00075-b90","series-title":"Cochrane Database Syst Rev","first-page":"CD008395","article-title":"Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months","volume":"11","author":"Enriquez","year":"2012","unstructured":"Enriquez A, Chu IW, Mellis C, et al. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. 2012;11:CD008395."},{"key":"JPPT-25-00075-b91","series-title":"N Engl J Med","first-page":"1096","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","unstructured":"Zhao S, Shang Y, Yin Y, et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection. N Engl J Med. 2024;391:1096\u2013107."},{"key":"JPPT-25-00075-b92","article-title":"Azithromycin treatment for respiratory syncytial virus-induced respiratory failure in children","unstructured":"National Library of Medicine. University of Alabama at Birmingham. Azithromycin treatment for respiratory syncytial virus-induced respiratory failure in children. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05026749"},{"issue":"4","key":"JPPT-25-00075-b93","series-title":"NEJM Evid","article-title":"Azithromycin to prevent recurrent wheeze following severe respiratory syncytial virus bronchiolitis","volume":"1","author":"Beigelman","year":"2022","unstructured":"Beigelman A, Srinivasan M, Goss CW, et al. Azithromycin to prevent recurrent wheeze following severe respiratory syncytial virus bronchiolitis. NEJM Evid. 2022;1(4):10.1056\/evidoa2100069."},{"issue":"6","key":"JPPT-25-00075-b94","series-title":"Pediatr Res","first-page":"1441","article-title":"Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis","volume":"95","author":"Ukkonen","year":"2024","unstructured":"Ukkonen RM, Renko M, Kuitunen I. Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis. Pediatr Res. 2024;95(6):1441\u20131447."},{"key":"JPPT-25-00075-b95","article-title":"Human interferon \u03b11b inhalation solution against respiratory syncytial virus in children with lower respiratory tract infections","unstructured":"National Library of Medicine. Kexing Biopharm Co., Ltd. Human interferon \u03b11b inhalation solution against respiratory syncytial virus in children with lower respiratory tract infections. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06363370"},{"key":"JPPT-25-00075-b96","article-title":"Children\u2019s Hospital of Soochow University. Peginterferon \u03b1-2b injection for the treatment of pediatric RSV bronchiolitis","unstructured":"National Library of Medicine. Children\u2019s Hospital of Soochow University. Peginterferon \u03b1-2b injection for the treatment of pediatric RSV bronchiolitis. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06827249"},{"key":"JPPT-25-00075-b97","article-title":"Study of obeldesivir to treat children with respiratory syncytial virus (RSV) infection","unstructured":"National Library of Medicine. Gilead Sciences. Study of obeldesivir to treat children with respiratory syncytial virus (RSV) infection. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06784973"},{"key":"JPPT-25-00075-b98","article-title":"Vigonvita Life Sciences. A study of deuremidevir hydrobromide for suspension in Chinese infants hospitalized with RSV","unstructured":"National Library of Medicine. Vigonvita Life Sciences. A study of deuremidevir hydrobromide for suspension in Chinese infants hospitalized with RSV. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06206720"},{"key":"JPPT-25-00075-b99","article-title":"PENTA Foundation. Safety, pharmacokinetics, and antiviral activity of remdesivir in hospitalized children with RSV (THAI-CARES RSV)","unstructured":"National Library of Medicine. PENTA Foundation. Safety, pharmacokinetics, and antiviral activity of remdesivir in hospitalized children with RSV (THAI-CARES RSV). Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06873633"},{"key":"JPPT-25-00075-b01","series-title":"Int J Infect Dis","first-page":"70","article-title":"Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study","volume":"135","author":"Du","year":"2023","unstructured":"Du Y, Yan R, Wu X, et al. Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: a systematic analysis of the Global Burden of Disease 2019 Study. Int J Infect Dis. 2023;135:70\u201376."},{"issue":"10340","key":"JPPT-25-00075-b02","series-title":"Lancet","first-page":"2047","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","unstructured":"Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u20132064."},{"issue":"Suppl 2","key":"JPPT-25-00075-b03","series-title":"J Infect Dis","first-page":"S154","article-title":"Respiratory syncytial virus is the leading cause of united states infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample","volume":"226","author":"Suh","year":"2022","unstructured":"Suh M, Movva N, Jiang X, et al. Respiratory syncytial virus is the leading cause of united states infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample. J Infect Dis. 2022;226(Suppl 2):S154\u2013S163."},{"key":"JPPT-25-00075-b04","series-title":"RSV surveillance & research","unstructured":"Centers for Disease Control Prevention. RSV surveillance & research. Updated August 30, 2024. Accessed November 22, 2024. https:\/\/www.cdc.gov\/rsv\/php\/surveillance\/index.html"},{"issue":"5","key":"JPPT-25-00075-b05","series-title":"J Infect Dis","first-page":"1318","article-title":"Annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus among US infants aged <12 months","volume":"231","author":"Houde","year":"2025","unstructured":"Houde L, Law AW, Averin A, et al. Annual clinical and economic burden of medically attended lower respiratory tract illnesses due to respiratory syncytial virus among US infants aged <12 months. J Infect Dis. 2025;231(5):1318\u20131326."},{"issue":"2","key":"JPPT-25-00075-b06","series-title":"J Pediatr Pharmacol Ther","first-page":"75","article-title":"Respiratory syncytial virus: diagnosis, treatment and prevention","volume":"14","author":"Eiland","year":"2009","unstructured":"Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75\u201385."},{"key":"JPPT-25-00075-b07","series-title":"Principles and Practice of Pediatric Infectious Diseases","first-page":"213","article-title":"Respiratory syncytial virus","author":"Tristram","year":"2003","unstructured":"Tristram DA, Welliver RC. Respiratory syncytial virus. In: Long SS, Pickering LK, Prober CG, editors. Principles and Practice of Pediatric Infectious Diseases. 2nd ed. New York, NY: Churchill Livingstone; 2003:213\u2013218."},{"issue":"3","key":"JPPT-25-00075-b08","series-title":"Proc Soc Exp Biol Med","first-page":"544","article-title":"Recovery of cytopathogenic agent from chimpanzees with coryza","volume":"92","author":"Blount","year":"1956","unstructured":"Blount Re Jr, Morris Ja, Savage Re. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 1956;92(3):544\u2013549."},{"issue":"Supplement_2","key":"JPPT-25-00075-b09","series-title":"J Pediatric Infect Dis Soc","first-page":"S103","article-title":"A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy","volume":"13","author":"Noor","year":"2024","unstructured":"Noor A, Krilov LR. A historical perspective on respiratory syncytial virus prevention: a journey spanning over half a century from the setback of an inactive vaccine candidate to the success of passive immunization strategy. J Pediatric Infect Dis Soc. 2024;13(Supplement_2):S103\u2013S109."},{"issue":"1","key":"JPPT-25-00075-b10","series-title":"Infect Dis Ther","first-page":"87","article-title":"Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children","volume":"7","author":"Sim\u00f5es","year":"2018","unstructured":"Sim\u00f5es EAF, Bont L, Manzoni P, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7(1):87\u2013120."},{"issue":"6136","key":"JPPT-25-00075-b11","series-title":"Science","first-page":"1113","article-title":"Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody","volume":"340","author":"McLellan","year":"2013","unstructured":"McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113\u20131117."},{"issue":"1","key":"JPPT-25-00075-b12","series-title":"Ann Pharmacother","first-page":"81","article-title":"Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children","volume":"59","author":"Fly","year":"2025","unstructured":"Fly JH, Eiland LS, Stultz JS. Nirsevimab: expansion of respiratory syncytial virus prevention options in neonates, infants, and at-risk young children. Ann Pharmacother. 2025;59(1):81\u201391."},{"issue":"8","key":"JPPT-25-00075-b13","series-title":"Ann Pharmacother","first-page":"758","article-title":"Maternal RSVpreF vaccine: a novel agent for respiratory syncytial virus prevention in infants","volume":"59","author":"Fly","year":"2025","unstructured":"Fly JH, Stultz JS, Eiland LS. Maternal RSVpreF vaccine: a novel agent for respiratory syncytial virus prevention in infants. Ann Pharmacother. 2025;59(8):758\u2013766."},{"issue":"3","key":"JPPT-25-00075-b14","series-title":"Cureus","first-page":"e36342","article-title":"Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation","volume":"15","author":"Kaler","year":"2023","unstructured":"Kaler J, Hussain A, Patel K, et al. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3):e36342."},{"issue":"4","key":"JPPT-25-00075-b15","series-title":"Nat Rev Microbiol","first-page":"233","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","unstructured":"Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233\u2013245."},{"issue":"14","key":"JPPT-25-00075-b16","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"355","article-title":"Seasonality of respiratory syncytial virus - United States, 2017-2023","volume":"72","author":"Hamid","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus - United States, 2017-2023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355\u2013361."},{"issue":"6","key":"JPPT-25-00075-b17","series-title":"Med Mal Infect","first-page":"377","article-title":"Respiratory syncytial virus infection in elderly adults","volume":"48","author":"Haber","year":"2018","unstructured":"Haber N. Respiratory syncytial virus infection in elderly adults. Med Mal Infect. 2018;48(6):377\u2013382."},{"issue":"3","key":"JPPT-25-00075-b18","series-title":"Am J Respir Crit Care Med","first-page":"308","article-title":"Evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies?","volume":"194","author":"Kulkarni","year":"2016","unstructured":"Kulkarni H, Smith CM, Lee Ddo H, et al. Evidence of respiratory syncytial virus spread by aerosol. time to revisit infection control strategies? Am J Respir Crit Care Med. 2016;194(3):308\u2013316."},{"key":"JPPT-25-00075-b19","series-title":"Douglas and Bennett\u2019s Principles and Practice of Infectious Diseases","first-page":"1782","article-title":"Respiratory syncytial virus","author":"Hall","year":"2000","unstructured":"Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett\u2019s Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingston; 2000:1782\u20131801"},{"issue":"3","key":"JPPT-25-00075-b20","series-title":"Respir Care","first-page":"209","article-title":"Systematic review of the biology and medical management of respiratory syncytial virus infection","volume":"48","author":"Black","year":"2003","unstructured":"Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care. 2003;48(3):209\u2013233."},{"issue":"10","key":"JPPT-25-00075-b21","series-title":"Thorax","first-page":"986","article-title":"Respiratory syncytial virus (RSV): a scourge from infancy to old age","volume":"74","author":"Coultas","year":"2019","unstructured":"Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019;74(10):986\u2013993."},{"issue":"Suppl B","key":"JPPT-25-00075-b22","series-title":"Respir Med","first-page":"S1","article-title":"An update on respiratory syncytial virus epidemiology: a developed country perspective","volume":"96","author":"Law","year":"2002","unstructured":"Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir Med. 2002;96 Suppl B:S1\u2013S7."},{"issue":"29","key":"JPPT-25-00075-b23","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1013","article-title":"Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021","volume":"70","author":"Olsen","year":"2021","unstructured":"Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013\u20131019."},{"issue":"1","key":"JPPT-25-00075-b24","series-title":"Mod Pathol","first-page":"108","article-title":"The histopathology of fatal untreated human respiratory syncytial virus infection","volume":"20","author":"Johnson","year":"2007","unstructured":"Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108\u2013119."},{"issue":"5","key":"JPPT-25-00075-b25","series-title":"Arch Dis Child","first-page":"428","article-title":"Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection","volume":"71","author":"Everard","year":"1994","unstructured":"Everard ML, Swarbrick A, Wrightham M, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child. 1994;71(5):428\u2013432."},{"issue":"14","key":"JPPT-25-00075-b26","series-title":"Int J Biol Sci","first-page":"4073","article-title":"Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies","volume":"17","author":"Shang","year":"2021","unstructured":"Shang Z, Tan S, Ma D. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies. Int J Biol Sci. 2021;17(14):4073\u20134091."},{"key":"JPPT-25-00075-b27","series-title":"BMJ","first-page":"f7027","article-title":"Duration of symptoms of respiratory tract infections in children: systematic review [published correction appears in BMJ. 2014;347:f7575]","volume":"347","author":"Thompson","year":"2013","unstructured":"Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review [published correction appears in BMJ. 2014;347:f7575]. BMJ. 2013;347:f7027."},{"issue":"11","key":"JPPT-25-00075-b28","series-title":"Pediatr Rev","first-page":"568","article-title":"Bronchiolitis","volume":"40","author":"Silver","year":"2019","unstructured":"Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev. 2019;40(11):568\u2013576."},{"issue":"3","key":"JPPT-25-00075-b29","series-title":"Demographics and outcome. Am J Dis Child","first-page":"247","article-title":"Respiratory syncytial virus-related apnea in infants","volume":"138","author":"Church","year":"1984","unstructured":"Church NR, Anas NG, Hall CB, et al Respiratory syncytial virus-related apnea in infants. Demographics and outcome. Am J Dis Child. 1984;138(3):247\u2013250."},{"issue":"3","key":"JPPT-25-00075-b30","series-title":"J Pediatr","first-page":"382","article-title":"Apnea associated with respiratory syncytial virus infection in young infants","volume":"90","author":"Bruhn","year":"1977","unstructured":"Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J Pediatr. 1977;90(3):382\u2013386."},{"issue":"16","key":"JPPT-25-00075-b31","series-title":"N Engl J Med","first-page":"1451","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","unstructured":"Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451\u20131464."},{"issue":"5","key":"JPPT-25-00075-b32","series-title":"N Engl J Med","first-page":"415","article-title":"Single-dose nirsevimab for prevention of RSV in preterm infants","volume":"383","author":"Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, et al; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415\u2013425."},{"issue":"9","key":"JPPT-25-00075-b33","series-title":"N Engl J Med","first-page":"837","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u2013846."},{"issue":"16","key":"JPPT-25-00075-b34","series-title":"N Engl J Med","first-page":"1533","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","unstructured":"Muller WJ, Madhi SA, Seoane Nu\u00f1ez B, et al; MELODY Study Group. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533\u20131534."},{"issue":"9","key":"JPPT-25-00075-b35","series-title":"N Engl J Med","first-page":"892","article-title":"Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity","volume":"386","author":"Domachowske","year":"2022","unstructured":"Domachowske J, Madhi SA, Sim\u00f5es EAF, et al; MEDLEY Study Group. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med. 2022;386(9):892\u2013894."},{"issue":"1","key":"JPPT-25-00075-b36","series-title":"Pediatrics","first-page":"e2023061803","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection","volume":"152","author":"Caserta","year":"2023","unstructured":"Caserta MT, O\u2019Leary ST, Munoz FM, et al. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2023;152(1):e2023061803."},{"issue":"6","key":"JPPT-25-00075-b37","series-title":"Am J Dis Child","first-page":"543","article-title":"Risk of primary infection and reinfection with respiratory syncytial virus","volume":"140","author":"Glezen","year":"1986","unstructured":"Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543\u2013546."},{"issue":"10","key":"JPPT-25-00075-b38","series-title":"N Engl J Med","first-page":"530","article-title":"Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children","volume":"300","author":"Henderson","year":"1979","unstructured":"Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med. 1979;300(10):530\u2013534."},{"issue":"4","key":"JPPT-25-00075-b39","series-title":"J Infect Dis","first-page":"814","article-title":"Severity of respiratory syncytial virus infection is related to virus strain","volume":"175","author":"Walsh","year":"1997","unstructured":"Walsh EE, McConnochie KM, Long CE, et al. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis. 1997;175(4):814\u2013820."},{"issue":"1","key":"JPPT-25-00075-b40","series-title":"J Infect Dis","first-page":"54","article-title":"Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons","volume":"193","author":"Gilca","year":"2006","unstructured":"Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193(1):54\u201358."},{"issue":"5","key":"JPPT-25-00075-b41","series-title":"Pediatrics","first-page":"e1474","article-title":"Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015;136(4):782. doi: 10.1542\/peds.2015-2862.]","volume":"134","author":"Ralston","year":"2014","unstructured":"Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015;136(4):782. doi: 10.1542\/peds.2015-2862.]. Pediatrics. 2014;134(5):e1474\u2013e1502."},{"issue":"11 Suppl","key":"JPPT-25-00075-b42","series-title":"Pediatr Infect Dis J","first-page":"S36","article-title":"Diagnostic assays for respiratory syncytial virus disease","volume":"26","author":"Henrickson","year":"2007","unstructured":"Henrickson KJ, Hall CB. Diagnostic assays for respiratory syncytial virus disease. Pediatr Infect Dis J. 2007;26(11 Suppl):S36\u2013S40."},{"issue":"11","key":"JPPT-25-00075-b43","series-title":"J Infect Dis","first-page":"1516","article-title":"Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis","volume":"228","author":"Onwuchekwa","year":"2023","unstructured":"Onwuchekwa C, Atwell J, Moreo LM, et al. Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis. J Infect Dis. 2023;228(11):1516\u20131527."},{"key":"JPPT-25-00075-b44","series-title":"Red Book: 2024-2027 Report of the Committee on Infectious Diseases","author":"Kimberlin","year":"2024","unstructured":"Kimberlin DW, Banerjee R, Barnett ED, et al. Red Book: 2024-2027 Report of the Committee on Infectious Diseases. 33rd ed. Washington, DC: American Academy of Pediatrics; 2024."},{"key":"JPPT-25-00075-b45","year":"2021","unstructured":"Palivizumab [package insert]. Gaithersburg, MD: MedImmune, LLC; 2021."},{"issue":"2","key":"JPPT-25-00075-b46","series-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics","first-page":"e620","article-title":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee","volume":"134","year":"2014","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):e620\u2013e638."},{"key":"JPPT-25-00075-b47","article-title":"AAP recommendations for the prevention of RSV disease in infants and children","unstructured":"American Academy of Pediatrics. AAP recommendations for the prevention of RSV disease in infants and children. Updated July 8, 2025. Accessed July 9, 2025. https:\/\/publications.aap.org\/redbook\/resources\/25379\/AAP-Recommendations-for-the-Prevention-of-RSV"},{"key":"JPPT-25-00075-b48","article-title":"SYNAGIS to be discontinued","unstructured":"Swedish Orphan Biovitrum. SYNAGIS to be discontinued. Accessed August 13, 2025. https:\/\/www.synagis.com\/index.html"},{"issue":"3 Pt 1","key":"JPPT-25-00075-b49","series-title":"Pediatrics","first-page":"):531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group","volume":"102","year":"1998","unstructured":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1 ):531\u2013537."},{"issue":"4","key":"JPPT-25-00075-b50","series-title":"J Pediatr","first-page":"532","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease","volume":"143","author":"Feltes","year":"2003","unstructured":"Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532\u2013540."},{"key":"JPPT-25-00075-b51","article-title":".","year":"2023","unstructured":"Beyfortus (nirsevimab-alip) [package insert] . S\u00f6dert\u00e4lje, Sweden: Astrazenca AB; 2023."},{"issue":"388","key":"JPPT-25-00075-b52","series-title":"Sci Transl Med","first-page":"eaaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","unstructured":"Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928."},{"issue":"9","key":"JPPT-25-00075-b53","series-title":"Vaccines (Basel)","first-page":"961","article-title":"Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities","volume":"9","author":"Ananworanich","year":"2021","unstructured":"Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines (Basel). 2021;9(9):961."},{"key":"JPPT-25-00075-b54","series-title":"Biomed Pharmacother","first-page":"115851","article-title":"Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults","volume":"169","author":"Phuah","year":"2023","unstructured":"Phuah JY, Maas BM, Tang A, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother. 2023;169:115851."},{"issue":"34","key":"JPPT-25-00075-b55","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"920","article-title":"Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Jones","year":"2023","unstructured":"Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920\u2013925."},{"issue":"41","key":"JPPT-25-00075-b56","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1115","article-title":"Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023","volume":"72","author":"Fleming-Dutra","year":"2023","unstructured":"Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115\u20131122."},{"issue":"3","key":"JPPT-25-00075-b57","series-title":"Lancet Child Adolesc Health","first-page":"180","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180\u2013189."},{"issue":"26","key":"JPPT-25-00075-b58","series-title":"N Engl J Med","first-page":"2425","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","unstructured":"Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425\u20132435."},{"issue":"4","key":"JPPT-25-00075-b59","series-title":"Pediatrics","first-page":"e2024066508","article-title":"Safety and pharmacokinetics of nirsevimab in immunocompromised children","volume":"154","author":"Domachowske","year":"2024","unstructured":"Domachowske J, Hamr\u00e9n UW, Banu I, et al. Safety and pharmacokinetics of nirsevimab in immunocompromised children. Pediatrics. 2024;154(4):e2024066508."},{"key":"JPPT-25-00075-b60","series-title":"package insert","year":"2025","unstructured":"Enflonsia (clesrovimab-cfor) [package insert]. Rahway, New Jersey: Merck Sharp & Dohme LLC; 2025."},{"key":"JPPT-25-00075-b61","article-title":"Child immunization schedule addendum","unstructured":"Centers for Disease Control and Prevention. Child immunization schedule addendum. Updated August 7, 2025. Accessed August 13, 2025. https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-addendum.html"},{"key":"JPPT-25-00075-b62","article-title":"Centers for Disease Control and Prevention, Sinha A. Clesrovimab (MK-1654): pediatric clinical program presentation to the Advisory Committee on Immunization Practices","unstructured":"Centers for Disease Control and Prevention, Sinha A. Clesrovimab (MK-1654): pediatric clinical program presentation to the Advisory Committee on Immunization Practices. Updated October 2024. Accessed February 27, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/02-rsv-mat-peds-sinha-508.pdf"},{"key":"JPPT-25-00075-b63","article-title":"Efficacy and safety of clesrovimab (MK-1654) in infants (MK-1654-004) (CLEVER)","unstructured":"National Library of Medicine. Merck Sharp & Dohme LLC. Efficacy and safety of clesrovimab (MK-1654) in infants (MK-1654-004) (CLEVER). Accessed February 27, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04767373"},{"key":"JPPT-25-00075-b64","article-title":"Clesrovimab (MK- 1654) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease (MK-1654-007) (SMART)","unstructured":"National Library of Medicine. Merck Sharp & Dohme LLC. Clesrovimab (MK- 1654) in infants and children at increased risk for severe respiratory syncytial virus (RSV) disease (MK-1654-007) (SMART). Accessed February 27, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04938830"},{"issue":"Suppl 1","key":"JPPT-25-00075-b65","series-title":"Open Forum Infect Dis","first-page":"ofae631.003","article-title":"Abstract 166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants","volume":"12","author":"Zar","year":"2025","unstructured":"Zar HJ, Simoes E, Madhi S, et al. Abstract 166. A phase 2b\/3 study to evaluate the efficacy and safety of an investigational respiratory syncytial virus (RSV) antibody, clesrovimab, in healthy preterm and full-term infants. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.003."},{"key":"JPPT-25-00075-b66","article-title":"Abryvso (Respiratory Syncytial Virus Vaccine) [package insert]","year":"2023","unstructured":"Abryvso (Respiratory Syncytial Virus Vaccine) [package insert]. New York, NY: Pfizer, Inc; 2023."},{"issue":"17","key":"JPPT-25-00075-b67","series-title":"N Engl J Med","first-page":"1615","article-title":"Prefusion F protein-based respiratory syncytial virus immunization in pregnancy","volume":"386","author":"Sim\u00f5es","year":"2022","unstructured":"Sim\u00f5es EAF, Center KJ, Tita ATN, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615\u20131626."},{"key":"JPPT-25-00075-b68","article-title":"Evidence to recommendations framework updates Pfizer maternal RSVpreF vaccine","author":"Fleming-Dutra","unstructured":"Centers for Disease Control and Prevention, Fleming-Dutra K. Evidence to recommendations framework updates Pfizer maternal RSVpreF vaccine. Updated September 2023. Accessed February 17, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-09-22\/06-Mat-Peds-Fleming-Dutra-508.pdf"},{"key":"JPPT-25-00075-b69","article-title":"Evidence to recommendations framework: Pfizer maternal RSVpreF vaccine. Updated","author":"Fleming-Dutra K","year":"2023","unstructured":"Centers for Disease Control and Prevention, Fleming-Dutra K. Evidence to recommendations framework: Pfizer maternal RSVpreF vaccine. Updated June 2023. Accessed February,26 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-06-21-23\/03-RSV-Mat-Ped-Fleming-Dutra-508.pdf"},{"issue":"21","key":"JPPT-25-00075-b70","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"489","article-title":"Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024 [published correction appears in MMWR Morb Mortal Wkly Rep. 2024;73(27):612. doi: 10.15585\/mmwr.mm7327a4.]","volume":"73","author":"Hause","year":"2024","unstructured":"Hause AM, Moro PL, Baggs J, et al. Early safety findings among persons aged \u226560 years who received a respiratory syncytial virus vaccine - United States, May 3, 2023-April 14, 2024 [published correction appears in MMWR Morb Mortal Wkly Rep. 2024;73(27):612. doi: 10.15585\/mmwr.mm7327a4.]. MMWR Morb Mortal Wkly Rep. 2024;73(21):489\u2013494."},{"key":"JPPT-25-00075-b71","series-title":"Updated October","first-page":"2024","article-title":"and","volume":"23","author":"Prevention","unstructured":"Centers for Disease Control and Prevention, DeSilva M. RSVpreF vaccine, preterm birth, and small for gestational age at birth preliminary results from the vaccine safety datalink. Updated October 23, 2024. Assessed February 26, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/03-RSV-Mat-Peds-DeSilva-508.pdf"},{"key":"JPPT-25-00075-b72","article-title":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV6120\/\u0394NS1 and RSV 6120\/F1\/G2\/\u0394NS1, in RSV-seropositive children and RSV-seronegative infants and children","unstructured":"National Library of Medicine. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of respiratory syncytial virus vaccines, RSV6120\/\u0394NS1 and RSV 6120\/F1\/G2\/\u0394NS1, in RSV-seropositive children and RSV-seronegative infants and children. Accessed May 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03596801"},{"key":"JPPT-25-00075-b73","article-title":"National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine, LID\/\u0394M2-2\/1030s, in RSV-seronegative infants and children 6 to 24 months of age","unstructured":"National Library of Medicine. National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine, LID\/\u0394M2-2\/1030s, in RSV-seronegative infants and children 6 to 24 months of age. Accessed May 1, 2025. https:\/\/clinicaltrials.gov\/study\/NCT04520659"},{"key":"JPPT-25-00075-b74","article-title":"Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting December 12, 2024. FDA briefing document. Considerations for respiratory syncytial virus (RSV) vaccine safety in pediatric populations","unstructured":"Food and Drug Administration Vaccines and Related Biological Products Advisory Committee Meeting December 12, 2024. FDA briefing document. Considerations for respiratory syncytial virus (RSV) vaccine safety in pediatric populations. Accessed May 1, 2025. https:\/\/www.fda.gov\/media\/184301\/download"},{"key":"JPPT-25-00075-b75","series-title":"Cochrane Database Syst Rev","first-page":"CD004873","article-title":"Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old","volume":"4","author":"Roqu\u00e9-Figuls","year":"2023","unstructured":"Roqu\u00e9-Figuls M, Gin\u00e9-Garriga M, Granados Rugeles C, et al. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database Syst Rev. 2023;4:CD004873."},{"key":"JPPT-25-00075-b76","series-title":"Cochrane Database Syst Rev","first-page":"CD010473","article-title":"Continuous positive airway pressure (CPAP) for acute bronchiolitis in children","volume":"4","author":"Jat","year":"2022","unstructured":"Jat KR, Dsouza JM, Mathew JL. Continuous positive airway pressure (CPAP) for acute bronchiolitis in children. Cochrane Database Syst Rev. 2022;4:CD010473."},{"key":"JPPT-25-00075-b77","series-title":"Cochrane Database Syst Rev","first-page":"CD009609","article-title":"High-flow nasal cannula therapy for infants with bronchiolitis","volume":"3","author":"Armarego","year":"2024","unstructured":"Armarego M, Forde H, Wills K, Beggs SA. High-flow nasal cannula therapy for infants with bronchiolitis. Cochrane Database Syst Rev. 2024;3:CD009609."},{"key":"JPPT-25-00075-b78","series-title":"Cochrane Database Syst Rev","first-page":"CD006458","article-title":"Nebulised hypertonic saline solution for acute bronchiolitis in infants","volume":"4","author":"Zhang","year":"2023","unstructured":"Zhang L, Mendoza-Sassi RA, Wainwright CE, et al. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev. 2023;4:CD006458."},{"issue":"9","key":"JPPT-25-00075-b79","series-title":"J Paediatr Child Health","first-page":"1125","article-title":"Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: a retrospective study","volume":"55","author":"Stobbelaar","year":"2019","unstructured":"Stobbelaar K, Kool M, de Kruijf D, et al. Nebulised hypertonic saline in children with bronchiolitis admitted to the paediatric intensive care unit: a retrospective study. J Paediatr Child Health. 2019;55(9):1125\u20131132."},{"key":"JPPT-25-00075-b80","series-title":"Cochrane Database Syst Rev","first-page":"CD006915","article-title":"Heliox inhalation therapy for bronchiolitis in infants","volume":"9","author":"Liet","year":"2015","unstructured":"Liet JM, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2015;9:CD006915."},{"key":"JPPT-25-00075-b81","series-title":"Cochrane Database Syst Rev","first-page":"CD001266","article-title":"Bronchodilators for bronchiolitis","volume":"6","author":"Gadomski","year":"2014","unstructured":"Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014;6:CD001266."},{"key":"JPPT-25-00075-b82","series-title":"Cochrane Database Syst Rev","first-page":"CD004878","article-title":"Glucocorticoids for acute viral bronchiolitis in infants and young children","volume":"6","author":"Fernandes","year":"2013","unstructured":"Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013;6:CD004878."},{"key":"JPPT-25-00075-b83","series-title":"Cochrane Database Syst Rev","first-page":"CD005189","article-title":"Antibiotics for bronchiolitis in children under two years of age","volume":"10","author":"Farley","year":"2014","unstructured":"Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 2014;10:CD005189."},{"issue":"10","key":"JPPT-25-00075-b84","series-title":"Cochrane Database Syst Rev","first-page":"CD009417","article-title":"Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection","volume":"10","author":"Sanders","year":"2023","unstructured":"Sanders SL, Agwan S, Hassan M, Bont LJ, Venekamp RP. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Cochrane Database Syst Rev. 2023;10(10):CD009417."},{"issue":"3","key":"JPPT-25-00075-b85","series-title":"Pediatrics","first-page":"e20182308","article-title":"Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial","volume":"143","author":"Alansari","year":"2019","unstructured":"Alansari K, Toaimah FH, Almatar DH, et al. Monoclonal antibody treatment of RSV bronchiolitis in young infants: a randomized trial. Pediatrics. 2019;143(3):e20182308."},{"key":"JPPT-25-00075-b86","series-title":"Cochrane Database Syst Rev","first-page":"CD009194","article-title":"Surfactant therapy for bronchiolitis in critically ill infants","volume":"8","author":"Jat","year":"2015","unstructured":"Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev. 2015;8:CD009194."},{"issue":"2","key":"JPPT-25-00075-b87","series-title":"Allergy Asthma Proc","first-page":"147","article-title":"Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial","volume":"31","author":"Zedan","year":"2010","unstructured":"Zedan M, Gamil N, El-Assmy M, et al. Montelukast as an episodic modifier for acute viral bronchiolitis: a randomized trial. Allergy Asthma Proc. 2010;31(2):147\u2013153."},{"issue":"6","key":"JPPT-25-00075-b88","series-title":"Pediatrics","first-page":"e1249","article-title":"A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis","volume":"122","author":"Amirav","year":"2008","unstructured":"Amirav I, Luder AS, Kruger N, et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics. 2008;122(6):e1249\u2013e1255."},{"key":"JPPT-25-00075-b89","series-title":"Cochrane Database Syst Rev","first-page":"CD010636","article-title":"Leukotriene inhibitors for bronchiolitis in infants and young children","volume":"3","author":"Liu","year":"2015","unstructured":"Liu F, Ouyang J, Sharma AN, et al. Leukotriene inhibitors for bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2015;3:CD010636."},{"key":"JPPT-25-00075-b90","series-title":"Cochrane Database Syst Rev","first-page":"CD008395","article-title":"Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months","volume":"11","author":"Enriquez","year":"2012","unstructured":"Enriquez A, Chu IW, Mellis C, et al. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. 2012;11:CD008395."},{"key":"JPPT-25-00075-b91","series-title":"N Engl J Med","first-page":"1096","article-title":"Ziresovir in hospitalized infants with respiratory syncytial virus infection","volume":"391","author":"Zhao","year":"2024","unstructured":"Zhao S, Shang Y, Yin Y, et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection. N Engl J Med. 2024;391:1096\u2013107."},{"key":"JPPT-25-00075-b92","article-title":"Azithromycin treatment for respiratory syncytial virus-induced respiratory failure in children","unstructured":"National Library of Medicine. University of Alabama at Birmingham. Azithromycin treatment for respiratory syncytial virus-induced respiratory failure in children. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT05026749"},{"issue":"4","key":"JPPT-25-00075-b93","series-title":"NEJM Evid","article-title":"Azithromycin to prevent recurrent wheeze following severe respiratory syncytial virus bronchiolitis","volume":"1","author":"Beigelman","year":"2022","unstructured":"Beigelman A, Srinivasan M, Goss CW, et al. Azithromycin to prevent recurrent wheeze following severe respiratory syncytial virus bronchiolitis. NEJM Evid. 2022;1(4):10.1056\/evidoa2100069."},{"issue":"6","key":"JPPT-25-00075-b94","series-title":"Pediatr Res","first-page":"1441","article-title":"Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis","volume":"95","author":"Ukkonen","year":"2024","unstructured":"Ukkonen RM, Renko M, Kuitunen I. Azithromycin for acute bronchiolitis and wheezing episodes in children - a systematic review with meta-analysis. Pediatr Res. 2024;95(6):1441\u20131447."},{"key":"JPPT-25-00075-b95","article-title":"Human interferon \u03b11b inhalation solution against respiratory syncytial virus in children with lower respiratory tract infections","unstructured":"National Library of Medicine. Kexing Biopharm Co., Ltd. Human interferon \u03b11b inhalation solution against respiratory syncytial virus in children with lower respiratory tract infections. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06363370"},{"key":"JPPT-25-00075-b96","article-title":"Children\u2019s Hospital of Soochow University. Peginterferon \u03b1-2b injection for the treatment of pediatric RSV bronchiolitis","unstructured":"National Library of Medicine. Children\u2019s Hospital of Soochow University. Peginterferon \u03b1-2b injection for the treatment of pediatric RSV bronchiolitis. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06827249"},{"key":"JPPT-25-00075-b97","article-title":"Study of obeldesivir to treat children with respiratory syncytial virus (RSV) infection","unstructured":"National Library of Medicine. Gilead Sciences. Study of obeldesivir to treat children with respiratory syncytial virus (RSV) infection. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06784973"},{"key":"JPPT-25-00075-b98","article-title":"Vigonvita Life Sciences. A study of deuremidevir hydrobromide for suspension in Chinese infants hospitalized with RSV","unstructured":"National Library of Medicine. Vigonvita Life Sciences. A study of deuremidevir hydrobromide for suspension in Chinese infants hospitalized with RSV. Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06206720"},{"key":"JPPT-25-00075-b99","article-title":"PENTA Foundation. Safety, pharmacokinetics, and antiviral activity of remdesivir in hospitalized children with RSV (THAI-CARES RSV)","unstructured":"National Library of Medicine. PENTA Foundation. Safety, pharmacokinetics, and antiviral activity of remdesivir in hospitalized children with RSV (THAI-CARES RSV). Accessed May 10, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06873633"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/3\/article-p322.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/3\/article-p322.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/3\/article-p322.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:46:16Z","timestamp":1781189176000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/3\/article-p322.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":198,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00075","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}